{"id":"W3093265161","doi":"10.1016/s0140-6736(10)60892-6","title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1636,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Susan G. Komen; Cancer Research Society; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Breast cancer; Cohort; PARP inhibitor; Internal medicine; BRCA mutation; Oncology; Adverse effect; Nausea; Cancer; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00184661,0.001856421,0.002952422,0.000344727,0.0003167197,0.001473098,0.0007711128,0.001977775,0.004449786],"category_scores_gemma":[0.001907976,0.0006280521,0.002164836,0.000450961,0.0009439848,0.00135371,0.0004043211,0.005409691,0.0008418506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009634982,"about_ca_system_score_gemma":0.001045932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007736528,"about_ca_topic_score_gemma":0.001581907,"domain_scores_codex":[0.9994687,0.0002607828,0.00002495645,0.00008664507,0.00004982117,0.0001091526],"domain_scores_gemma":[0.9991065,0.0003989649,0.0001190372,0.00005346479,0.00004659272,0.0002755847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8837184,0.005225741,0.00108139,0.001591209,0.001846767,0.0001879723,0.0001098361,0.001233841,0.004644841,0.0004055957,0.00393058,0.09602389],"study_design_scores_gemma":[0.9293479,0.06292742,0.001682092,0.0001168119,0.0008045891,0.0001593467,0.00004162353,0.0005813358,0.0006395478,0.0004770244,0.003194146,0.00002826264],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9291678,0.04714403,0.002375969,0.005323501,0.001967963,0.003358099,0.002997374,0.0002683907,0.007396844],"genre_scores_gemma":[0.96641,0.01910131,0.002457652,0.00355571,0.0006774373,0.001696926,0.001710911,0.00004670944,0.004343296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004449786,"threshold_uncertainty_score":0.01488602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01882420731186658,"score_gpt":0.3056834608736979,"score_spread":0.2868592535618313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}